Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.63 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.63 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.43 |
| ▸ | TERF2IP | Q9NYB0 | 4/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | FCGRT | P55899 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386852 | 1.00 | KDM1A (0.63) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL17882201 | 0.93 | KDM1A (0.60) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL19386920 | 0.93 | KDM1A (0.60) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL19386820 | 0.92 | KDM1A (0.66) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL17882079 | 0.92 | KDM1A (0.66) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL25623669 | 0.92 | KDM1A (0.66) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL19386914 | 0.92 | KDM1A (0.66) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL17882034 | 0.91 | KDM1A (0.58) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL17882084 | 0.91 | KDM1A (0.70) | KDM1ARCOR1SSTR2TERF2IPF11 | |
| SCHEMBL19386933 | 0.91 | KDM1A (0.65) | KDM1ARCOR1SSTR2TERF2IPF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | KDM1A 4119/4885RCOR1 4858/4885SSTR2 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.